2020
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study
Finnema SJ, Toyonaga T, Detyniecki K, Chen M, Dias M, Wang Q, Lin S, Naganawa M, Gallezot J, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study. Epilepsia 2020, 61: 2183-2193. PMID: 32944949, DOI: 10.1111/epi.16653.Peer-Reviewed Original ResearchConceptsMedial temporal lobe sclerosisTemporal lobe epilepsyTLE subjectsPositron emission tomographyLobe epilepsyJ BPSynaptic vesicle protein 2APartial volume correctionTemporal lobe sclerosisPositron emission tomography studyEmission tomography studiesSeizure onset zonePromising biomarker approachJ bindingPresurgical selectionSclerotic hippocampusHippocampal asymmetryTLE patientsRegional binding patternsControl subjectsCentrum semiovaleContralateral regionsEpilepsy patientsOutcome measuresOnset zone
2019
In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease
Toyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE. In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. Journal Of Nuclear Medicine 2019, 60: 1780-1786. PMID: 31101744, PMCID: PMC6894376, DOI: 10.2967/jnumed.118.223867.Peer-Reviewed Original ResearchConceptsAPP/PS1 micePS1 miceAlzheimer's diseaseWT miceSynaptic densityC-UCBDrug washoutTreatment effectsPresenilin 1 (PS1) double transgenic miceHippocampal synaptic densityAPP/PS1Double transgenic miceEnd of treatmentWild-type miceAmyloid precursor proteinEarly Alzheimer's diseaseSignificant differencesSUVR-1New PET tracersMild cognitive impairmentAD miceSynaptic deficitsOral gavageAD treatmentHealthy subjects
2016
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, Terasaka S, Kobayashi H, Hattori N, Shiga T, Kuge Y, Tanaka S, Ito YM, Tamaki N. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 44: 611-619. PMID: 27752745, DOI: 10.1007/s00259-016-3541-z.Peer-Reviewed Original ResearchConceptsProgression-free survivalExtent of resectionStandardized uptake valuePositron emission tomographyGross tumor volumeFMISO positron emission tomographyMagnetic resonance imagingKarnofsky Performance ScaleOverall survivalTumor volumeGlioblastoma patientsHypoxia volumeFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyPotential prognostic factorsTotal lesion glycolysisMetabolic tumor volumeHypoxic volumeVolume of interestGadolinium-enhanced T1-weighted MR imagesReference regionT1-weighted MR imagesCytoreduction surgeryFree survivalPrognostic factors18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 43: 1469-1476. PMID: 26841941, DOI: 10.1007/s00259-016-3320-x.Peer-Reviewed Original ResearchConceptsPresence of necrosisBrain tumorsFMISO PETFMISO uptakeSevere hypoxiaFMISO PET/Brain tumor patientsPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerHistopathological necrosisPathological necrosisPoor prognosisSurgical strategyIntratumoral necrosisNeuroepithelial tumorsTumor resectionPathological diagnosisTumor patientsCerebellum ratioTreatment decisionsMethodsThis studyGroup 2Group 1Experienced neuropathologist